{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:45:02Z","timestamp":1790700302446,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The association between human leukocyte antigen (HLA)-B*58:01 and risk of allopurinol-induced severe cutaneous adverse reactions (AIS) was observed across different populations. We explore the association between HLA-B*58:01 and AIS risk in multiethnic Malaysian population. The HLA-B*58:01 risk for different AIS clinical phenotypes and ethnicity was determined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed a case-control association study by genotyping the HLA-B alleles of 55 patients with AIS [11 toxic epidermal necrolysis (TEN), 21 Steven Johnson syndrome (SJS) 22 drug reaction wit eosinophilia and systemic symptoms (DRESS) and one acute generalized exanthematous pustulosis (AGEP)] and 42 allopurinol-tolerant controls (ATC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>HLA-B*58:01 was positive in 89.1 and 14.3% of the AIS and ATC study groups [odds ratio (OR) = 49.0, 95% confidence interval (CI) = 14.6\u2013164.4, P &lt; 0.0001)], respectively. Our data showed that 93.8% of the AIS-SJS\/TEN patients and 86.4% of the AIS-DRESS patients were HLA-B*58:01 positive (AIS-SJS\/TEN, OR = 90, 95% CI = 16.9\u2013470.1, P &lt; 0.0001 and AIS-DRESS OR = 38, 95% CI = 8.5\u2013169.2, P &lt; 0.0001). Stratification by ethnicity and clinical phenotypes revealed a significant increased risk between HLA-B*58:01 and Chinese-AIS patients (OR = 137.5, 95% CI = 11.3\u20131680.2, P &lt; 0.0001), in particular Chinese patients with AIS-SJS\/TEN phenotype (100% HLA-B*58:01 positive). HLA-B*58:01 was positive in 90.9% Chinese AIS-DRESS (P &lt; 0.0001). Highly significant associations of HLA-B*58:01 were observed in Malay AIS-SJS\/TEN (OR = 78, 95% CI = 9.8\u2013619.9, P &lt; 0.0001) and Malay AIS-DRESS (OR = 54, 95% CI = 6.6\u2013442.9, P &lt; 0.0001). Although the number of Indian-AIS patients was relatively small (n = 2), both were HLA-B*58:01 positive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our data suggest strong associations between HLA-B*58:01 and AIS in Malaysian population with Chinese and Malays ethnicity. The strong association was also observed in three different clinical phenotypes of AIS, mainly the AIS-SJS\/TEN<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000408","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:42:48Z","timestamp":1590010968000},"page":"153-160","source":"Crossref","is-referenced-by-count":18,"title":["HLA-B*58:01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia"],"prefix":"10.1097","volume":"30","author":[{"given":"Dyoi E","family":"Low","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Kuala Lumpur, Ministry of Health Malaysia"},{"name":"Department of Dermatology, Hospital Serdang, Ministry of Health Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Fauzi","family":"Nurul-Aain","sequence":"additional","affiliation":[{"name":"Immunogenetic Unit, Allergy and Immunology Research Center, Institute for Medical Research, Ministry of Health Malaysia, Kuala Lumpur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooi Chiang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Serdang, Ministry of Health Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyh Jong","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Raja Permaisuri Bainun, Ministry of Health Malaysia, Perak"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Faizal","family":"Bakhtiar","sequence":"additional","affiliation":[{"name":"Allergy Unit, Allergy and Immunology Research Center, Institute for Medical Research, Ministry of Health Malaysia, Kuala Lumpur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Murad","sequence":"additional","affiliation":[{"name":"Office of Deputy Director General of Health, Ministry of Health Malaysia, Putrajaya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong Chor","family":"Chang","sequence":"additional","affiliation":[{"name":"Gleneagles Kuala Lumpur, Jalan Ampang, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Lai","family":"Too","sequence":"additional","affiliation":[{"name":"Immunogenetic Unit, Allergy and Immunology Research Center, Institute for Medical Research, Ministry of Health Malaysia, Kuala Lumpur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Moon","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Kuala Lumpur, Ministry of Health Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1471-2369-14-164","article-title":"The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality.","volume":"14","author":"Gustafsson","year":"2013","journal-title":"BMC Nephrol"},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"19520","DOI":"10.1038\/srep19520","article-title":"Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis.","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1468-3083.2011.04313.x","article-title":"Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department\u2013Cagliari University (Italy).","volume":"26","author":"Atzori","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.12.89","article-title":"HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.","volume":"13","author":"Cao","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong.","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1744-313X.2011.01011.x","article-title":"A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"38","author":"Cristallo","year":"2011","journal-title":"Int J Immunogenet"},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population.","volume":"169","author":"Gon\u00e7alo","year":"2013","journal-title":"Br J Dermatol"},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1445-5994.2011.02567.x","article-title":"Initiating allopurinol therapy: do we need to know the patient\u2019s human leucocyte antigen status?","volume":"42","author":"Lee","year":"2012","journal-title":"Intern Med J"},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fphar.2016.00186","article-title":"HLA-B (*) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand.","volume":"7","author":"Sukasem","year":"2016","journal-title":"Front Pharmacol"},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/tpj.2011.41","article-title":"A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.","volume":"13","author":"Tohkin","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"R19-20230911","first-page":"4","article-title":"Allopurinol: impact of risk minimisation actions.","volume":"1","author":"Panicker","year":"2014","journal-title":"MADRAC Newsletter"},{"key":"R20-20230911","first-page":"1","article-title":"Allopurinol: an update on usage in the Ministry of Health Facilities and related adverse cutaneous drug reactions.","volume":"2","author":"Hiriraj","year":"2012","journal-title":"MADRAC Newsletter"},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population.","volume":"50","author":"Chang","year":"2011","journal-title":"Int J Dermatol"},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/tpj.2016.10","article-title":"Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population.","volume":"17","author":"Chang","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity.","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study.","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS.","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"R28-20230911","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archdermatol.2010.198","article-title":"Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases.","volume":"146","author":"Chen","year":"2010","journal-title":"Arch Dermatol"},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1468-3083.2008.02585.x","article-title":"Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan.","volume":"22","author":"Chiou","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R31-20230911","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000069956","article-title":"Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update.","volume":"206","author":"Tas","year":"2003","journal-title":"Dermatology"},{"key":"R32-20230911","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u2013a clinical reaction pattern.","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"R33-20230911","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients.","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute generalized exanthematous pustulosis (AGEP): a review and update.","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R36-20230911","first-page":"2","article-title":"Stevens Johnson syndrome and toxic epidermal necrolysis associated with the use of allopurinol.","volume":"1","year":"2008","journal-title":"MADRAC Newsletter"},{"key":"R37-20230911","first-page":"6","article-title":"Allopurinol-Induced Adverse cutaneous drug reactions: a review of MADRAC (Malaysian Adverse Drug Reactions Advisory Committee) report from 2000 \u2013 2009.","volume":"3","author":"Lee","year":"2010","journal-title":"MADRAC Newsletter"},{"key":"R38-20230911","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/rheumatology\/kex422","article-title":"How to prevent allopurinol hypersensitivity reactions?","volume":"57","author":"Stamp","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk.","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R40-20230911","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/jid.2015.165","article-title":"Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions.","volume":"135","author":"Chung","year":"2015","journal-title":"J Invest Dermatol"},{"key":"R41-20230911","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tan.13183","article-title":"HLAs: key regulators of T-cell-mediated drug hypersensitivity.","volume":"91","author":"Redwood","year":"2018","journal-title":"HLA"},{"key":"R42-20230911","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","article-title":"Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01.","volume":"192","author":"Yun","year":"2014","journal-title":"J Immunol"},{"key":"R43-20230911","first-page":"1187","article-title":"Racial\/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study.","volume":"77","author":"Keller","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R44-20230911","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s10067-017-3851-y","article-title":"Asymptomatic hyperuricemia: is it time to intervene?","volume":"36","author":"Paul","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R45-20230911","doi-asserted-by":"crossref","first-page":"257","DOI":"10.23876\/j.krcp.19.074","article-title":"To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease.","volume":"38","author":"Shin","year":"2019","journal-title":"Kidney Res Clin Pract"},{"key":"R46-20230911","doi-asserted-by":"crossref","first-page":"594, 597, 600","DOI":"10.3949\/ccjm.69.8.594","article-title":"Asymptomatic hyperuricemia: to treat or not to treat.","volume":"69","author":"Dincer","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"R47-20230911","doi-asserted-by":"crossref","first-page":"e94294","DOI":"10.1371\/journal.pone.0094294","article-title":"Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population.","volume":"9","author":"Saokaew","year":"2014","journal-title":"PLoS One"},{"key":"R48-20230911","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2217\/pgs.15.125","article-title":"Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.","volume":"16","author":"Dong","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R49-20230911","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/acr.22409","article-title":"Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.","volume":"67","author":"Park","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R50-20230911","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R51-20230911","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.151476","article-title":"Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions.","volume":"44","author":"Ke","year":"2017","journal-title":"J Rheumatol"},{"key":"R52-20230911","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/FPC.0000000000000319","article-title":"Cost-effectiveness analysis of HLA-B*58.","volume":"28","author":"Chong","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"R54-20230911","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1093\/hmg\/ddu149","article-title":"Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations.","volume":"23","author":"Pillai","year":"2014","journal-title":"Hum Mol Genet"},{"key":"R55-20230911","doi-asserted-by":"crossref","first-page":"762820","DOI":"10.1155\/2015\/762820","article-title":"Prevalence of hyperuricemia and gout in Mainland China from 2000 to 2014: a systematic review and meta-analysis.","volume":"2015","author":"Liu","year":"2015","journal-title":"Biomed Res Int"},{"key":"R56-20230911","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10067-011-1699-0","article-title":"Prevalence of hyperuricemia in Bangkok population.","volume":"30","author":"Uaratanawong","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R58-20230911","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.1780290111","article-title":"The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality.","volume":"29","author":"Singer","year":"1986","journal-title":"Arthritis Rheum"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:17:55Z","timestamp":1694409475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000408","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,19]]}}}